vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Five9, Inc. (FIVN). Click either name above to swap in a different company.
Five9, Inc. is the larger business by last-quarter revenue ($300.3M vs $183.1M, roughly 1.6× Amphastar Pharmaceuticals, Inc.). On growth, Five9, Inc. posted the faster year-over-year revenue change (7.8% vs -1.8%). Five9, Inc. produced more free cash flow last quarter ($77.3M vs $24.6M). Over the past eight quarters, Five9, Inc.'s revenue compounded faster (10.3% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Five9, Inc. is a leading global provider of cloud-native contact center software and solutions. It serves enterprises of all sizes across retail, healthcare, financial services, and technology sectors, offering omnichannel customer engagement tools, AI-powered automation, workforce management, and analytics to boost customer experience and operational efficiency.
AMPH vs FIVN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $300.3M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | 55.4% |
| Operating Margin | 19.4% | 6.6% |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | 7.8% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $300.3M | ||
| Q3 25 | $191.8M | $285.8M | ||
| Q2 25 | $174.4M | $283.3M | ||
| Q1 25 | $170.5M | $279.7M | ||
| Q4 24 | $186.5M | $278.7M | ||
| Q3 24 | $191.2M | $264.2M | ||
| Q2 24 | $182.4M | $252.1M | ||
| Q1 24 | $171.8M | $247.0M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $18.0M | ||
| Q2 25 | $31.0M | $1.2M | ||
| Q1 25 | $25.3M | $576.0K | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-4.5M | ||
| Q2 24 | $37.9M | $-12.8M | ||
| Q1 24 | $43.2M | $-7.1M |
| Q4 25 | 46.8% | 55.4% | ||
| Q3 25 | 51.4% | 55.0% | ||
| Q2 25 | 49.6% | 54.9% | ||
| Q1 25 | 50.0% | 55.0% | ||
| Q4 24 | 46.5% | 56.0% | ||
| Q3 24 | 53.3% | 53.8% | ||
| Q2 24 | 52.2% | 53.0% | ||
| Q1 24 | 52.4% | 53.6% |
| Q4 25 | 19.4% | 6.6% | ||
| Q3 25 | 13.2% | 5.6% | ||
| Q2 25 | 24.2% | -0.6% | ||
| Q1 25 | 21.9% | -1.9% | ||
| Q4 24 | 24.2% | 1.5% | ||
| Q3 24 | 29.8% | -5.8% | ||
| Q2 24 | 30.3% | -7.7% | ||
| Q1 24 | 27.9% | -8.4% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 6.3% | ||
| Q2 25 | 17.8% | 0.4% | ||
| Q1 25 | 14.8% | 0.2% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -1.7% | ||
| Q2 24 | 20.8% | -5.1% | ||
| Q1 24 | 25.1% | -2.9% |
| Q4 25 | $0.51 | $0.22 | ||
| Q3 25 | $0.37 | $0.21 | ||
| Q2 25 | $0.64 | $0.01 | ||
| Q1 25 | $0.51 | $0.01 | ||
| Q4 24 | $0.74 | $0.16 | ||
| Q3 24 | $0.78 | $-0.06 | ||
| Q2 24 | $0.73 | $-0.17 | ||
| Q1 24 | $0.81 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $232.1M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $785.8M |
| Total Assets | $1.6B | $1.8B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $232.1M | ||
| Q3 25 | $276.2M | $193.4M | ||
| Q2 25 | $231.8M | $205.5M | ||
| Q1 25 | $236.9M | $370.3M | ||
| Q4 24 | $221.6M | $362.5M | ||
| Q3 24 | $250.5M | $291.0M | ||
| Q2 24 | $217.8M | $175.7M | ||
| Q1 24 | $289.6M | $240.2M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $785.8M | ||
| Q3 25 | $776.7M | $775.3M | ||
| Q2 25 | $757.5M | $717.4M | ||
| Q1 25 | $751.3M | $664.3M | ||
| Q4 24 | $732.3M | $622.2M | ||
| Q3 24 | $727.7M | $565.6M | ||
| Q2 24 | $713.3M | $525.9M | ||
| Q1 24 | $672.4M | $483.6M |
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.7B | $1.8B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.6B | $2.1B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.5B | $1.9B | ||
| Q1 24 | $1.6B | $1.9B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $83.6M |
| Free Cash FlowOCF − Capex | $24.6M | $77.3M |
| FCF MarginFCF / Revenue | 13.4% | 25.8% |
| Capex IntensityCapex / Revenue | 4.5% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $201.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $83.6M | ||
| Q3 25 | $52.6M | $59.2M | ||
| Q2 25 | $35.6M | $35.1M | ||
| Q1 25 | $35.1M | $48.4M | ||
| Q4 24 | $29.0M | $49.8M | ||
| Q3 24 | $60.0M | $41.1M | ||
| Q2 24 | $69.1M | $19.9M | ||
| Q1 24 | $55.3M | $32.4M |
| Q4 25 | $24.6M | $77.3M | ||
| Q3 25 | $47.2M | $48.7M | ||
| Q2 25 | $25.0M | $31.6M | ||
| Q1 25 | $24.4M | $43.7M | ||
| Q4 24 | $16.6M | $40.5M | ||
| Q3 24 | $46.2M | $26.7M | ||
| Q2 24 | $63.1M | $13.1M | ||
| Q1 24 | $46.5M | $20.4M |
| Q4 25 | 13.4% | 25.8% | ||
| Q3 25 | 24.6% | 17.0% | ||
| Q2 25 | 14.3% | 11.1% | ||
| Q1 25 | 14.3% | 15.6% | ||
| Q4 24 | 8.9% | 14.5% | ||
| Q3 24 | 24.1% | 10.1% | ||
| Q2 24 | 34.6% | 5.2% | ||
| Q1 24 | 27.1% | 8.3% |
| Q4 25 | 4.5% | 2.1% | ||
| Q3 25 | 2.8% | 3.7% | ||
| Q2 25 | 6.1% | 1.2% | ||
| Q1 25 | 6.3% | 1.7% | ||
| Q4 24 | 6.7% | 3.3% | ||
| Q3 24 | 7.2% | 5.4% | ||
| Q2 24 | 3.3% | 2.7% | ||
| Q1 24 | 5.1% | 4.8% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 3.29× | ||
| Q2 25 | 1.15× | 30.38× | ||
| Q1 25 | 1.39× | 84.00× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FIVN
Segment breakdown not available.
